Monday, October 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· April 21, 2026

Introducing Osirus AI, the Unified Platform for Building, Deploying, and Managing Enterprise AI Agents

View original at globenewswire.com
Introducing Osirus AI, the Unified Platform for Building, Deploying, and Managing Enterprise AI Agents ST. PETERSBURG, Fla., April 21, 2026 (GLOBE NEWSWIRE) -- Osirus AI today announced the public launch of its enterprise AI platform, built from the ground up by three founders with no outside funding…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI agents are one of ARK Invest's central investment themes for 2026, with projected capital investment in AI infrastructure to reach $1.4 trillion by 2030

    60% confidence

  • Enterprise AI agent platforms are a key area of disruptive innovation

    60% confidence

  • AI isn't just about models anymore – it's about the agents doing the work. Osirus is the system enterprises need to build, deploy, and manage agents with visibility and control so that they can scale them across their business.

    60% confidence

  • The organizations getting real value from AI right now are not replacing their people — they are promoting them. You train an agent on your content, deploy it to the front line, and your team manages it like any other employee: reviewing its work, correcting mistakes, and making it better every day.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com